Brief: Helix Biopharma initiates enrollment in the third dosing cohort of its lung cancer drug l-DOS47
25/07/2017 21:31
July 25 (Reuters) - Helix Biopharma Corp HBP.TO
* Helix Biopharma Corp initiates enrollment in the third
dosing cohort of U.S. combination treatment study of its lung
cancer drug candidate l-DOS47
Source text for Eikon: ID:nMKWTW7bsa
Further company coverage: HBP.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020